CLL/SLL,   DLBCL,  FL,  HL,  MCL,  MZL

Bechara Mfarrej | EBMT 2018 | Advice for the management of toxicities in CAR-T

L: English

  • Bechara Mfarrej discusses cytokine release syndrome (CRS) that is a potentially serious side-effect of CAR-T therapy. 
  • He explains that these side-effects are managed by supportive care but it is important to control the symptoms without eliminating the CAR-T cells.
  • Most toxicities are manageable with dedicated supportive care, he concluded, and cytokine blocking medication can be given in the most extreme cases. 
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Bechara Mfarrej Institute Paoli-Calmettes, Marseille, FR
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF